Shamburg News · 8-K filed Nov 12, 2026, 8:08 AM EST

Avalyn Pharma Reports Third Quarter 2026 Net Loss of $29.7 Million

AVLN · Avalyn Pharma Inc.

  • Earnings
  • Financial statements
  • Materiality: high

Avalyn Pharma Inc. announced financial results for the quarter ended September 30, 2026, reporting a net loss of $29.7 million compared with $23.6 million a year earlier. R&D expenses were $25.5 million and G&A expenses were $7.6 million for the quarter. The company reported cash, cash equivalents and marketable securities of $386.6 million as of September 30, 2026, and projects they will fund operations into 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-457053.

Written from the filing by Shamburg Markets. Figures are as reported by the company.